News

Innovent Biologics Lands $8.5 Billion Eli Lilly Partnership for Oncology and Immunology Development

Araverus Team|Monday, February 9, 2026 at 5:57 AM

Araverus Team

Feb 9, 2026 · 5:57 AM

Biotech Partnership · Cancer Treatments · Eli Lilly · Innovent Biologics

Biotech Partnership Cancer Treatments Eli Lilly Innovent Biologics

Innovent Biologics has formed a partnership with Eli Lilly to develop treatments for cancer and immune system diseases, with potential milestone payments reaching up to $8.5 billion.

Innovent Biologics Lands $8.5 Billion Eli Lilly Partnership for Oncology and Immunology Development

Read More On

Related Articles

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion

AbbVie Revenue Rises on Immunology Growth

Biogen Revenue Down as Multiple Sclerosis Sales Slide

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S.

Innovent Biologics Lands $8.5 Billion Eli Lilly Partnership for Oncology and Immunology Development

Read More On

Related Articles

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion

AbbVie Revenue Rises on Immunology Growth

Biogen Revenue Down as Multiple Sclerosis Sales Slide

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S.